Thompson Siegel & Walmsley LLC Has $15.05 Million Holdings in QuidelOrtho Co. (NASDAQ:QDEL)

Thompson Siegel & Walmsley LLC boosted its stake in QuidelOrtho Co. (NASDAQ:QDEL) by 33.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 337,860 shares of the company’s stock after purchasing an additional 85,405 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in QuidelOrtho were worth $15,052,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of QDEL. Point72 Asset Management L.P. acquired a new stake in QuidelOrtho in the third quarter valued at $34,320,000. Rubric Capital Management LP increased its holdings in QuidelOrtho by 15.2% in the third quarter. Rubric Capital Management LP now owns 4,200,000 shares of the company’s stock valued at $191,520,000 after purchasing an additional 554,410 shares during the period. Segall Bryant & Hamill LLC acquired a new stake in QuidelOrtho in the third quarter valued at $19,565,000. Beaconlight Capital LLC acquired a new stake in QuidelOrtho in the third quarter valued at $18,152,000. Finally, State Street Corp increased its holdings in QuidelOrtho by 16.9% in the third quarter. State Street Corp now owns 1,907,898 shares of the company’s stock valued at $87,000,000 after purchasing an additional 275,522 shares during the period. 99.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. UBS Group increased their price target on QuidelOrtho from $43.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, February 13th. William Blair reiterated a “market perform” rating on shares of QuidelOrtho in a report on Wednesday, November 20th. Citigroup upgraded QuidelOrtho from a “neutral” rating to a “buy” rating and increased their price target for the stock from $44.00 to $50.00 in a report on Wednesday, December 11th. Royal Bank of Canada decreased their price target on QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating for the company in a report on Thursday, February 13th. Finally, StockNews.com downgraded QuidelOrtho from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $51.20.

QuidelOrtho Price Performance

QDEL stock opened at $36.87 on Thursday. The stock has a market capitalization of $2.49 billion, a PE ratio of -1.22 and a beta of 0.10. The company’s 50-day moving average is $42.29 and its 200-day moving average is $42.07. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 0.69. QuidelOrtho Co. has a 1 year low of $29.74 and a 1 year high of $49.45.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 3.78% and a negative net margin of 72.84%. Equities research analysts expect that QuidelOrtho Co. will post 2.3 EPS for the current fiscal year.

QuidelOrtho Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.